Immune Checkpoint Inhibitor-Induced Autoimmune Diabetes

Immune checkpoint inhibitors have revolutionised oncology by unleashing T cell–mediated antitumour responses through blockade of inhibitory receptors such as PD-1 and CTLA-4. A rare but severe consequence of this immune reactivation is autoimmune diabetes, characterised by rapid destruction of pancreatic β cells. Clinical onset is often abrupt, frequently presenting with diabetic ketoacidosis and marked loss of endogenous insulin secretion as measured by C-peptide. Autoantibody profiles may be positive or absent, and genetic predisposition does not reliably predict risk. Imaging studies demonstrate pancreatic atrophy in many affected individuals. Management requires lifelong insulin replacement and involves multidisciplinary collaboration to balance oncological benefit with endocrine toxicity. Emerging proteomic and immunophenotypic analyses suggest that specific inflammatory and metabolic markers may herald disease onset, while mechanistic studies highlight the central role of cytokine-driven β cell injury. Understanding this toxicity has global importance as the use of checkpoint inhibitors expands across cancer types, emphasising the need for vigilant glucose monitoring and tailored immunomodulatory strategies to preserve both metabolic and oncological outcomes.

Research from Nature Portfolio

Recent studies have elucidated how local inflammatory signals modulate β cell resilience during checkpoint blockade. Work in both mouse models and human islets demonstrated that interferon-γ drives upregulation of PD-L1 on β cells in the face of insulitis, serving as a brake on autoreactive T cells. Loss of this adaptive PD-L1 expression under PD-1 pathway inhibition accelerates β cell destruction. The study revealed that β cell-intrinsic regulation of checkpoint ligand expression is not merely passive but represents a dynamic defence mechanism; its impairment underlies the fulminant onset of autoimmune diabetes in patients receiving PD-1–targeted therapies.

Immune Checkpoint Inhibitor-Induced Autoimmune Diabetes publication trend

The graph below shows the total number of articles in immune checkpoint inhibitor-induced autoimmune diabetes across all publications each year (not limited to Nature Index journals).

Technical terms

Immune checkpoint inhibitor: A therapeutic antibody that blocks inhibitory receptors on T cells to enhance antitumour immunity.

Programmed death ligand-1 (PD-L1): A cell-surface protein that binds PD-1 on T cells to restrain immune activation.

C-peptide: A peptide fragment released during insulin synthesis, used as a marker of endogenous insulin production.

Diabetic ketoacidosis: A life-threatening metabolic crisis characterised by hyperglycaemia, ketosis and acidosis.

Autoantibody: An antibody directed against self-antigens, often used to define autoimmune diabetes subtypes.

References

1. A single center case series of immune checkpoint inhibitor-induced type 1 diabetes mellitus, patterns of disease onset and long-term clinical outcome. Frontiers in Immunology (2023).
2. Checkpoint Inhibitor-Associated Autoimmune Diabetes Mellitus Is Characterized by C-peptide Loss and Pancreatic Atrophy. The Journal of Clinical Endocrinology & Metabolism (2023).
3. Interferon-gamma drives programmed death-ligand 1 expression on islet β cells to limit T cell function during autoimmune diabetes. Scientific Reports (2018).
4. Immune cells and their inflammatory mediators modify beta cells and cause checkpoint inhibitor-induced diabetes. JCI Insight (2022).